Do analysts rate HVO or SCLP?

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts plainly believe hVIVO is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, HVO or SCLP?

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.02 £17.84M -£0.87 N/A Scancell £4.71M 40.53 -£6.75M -£0.55 N/A

Is HVO or SCLP more profitable?

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Scancell -116.98% 90.29% -45.28%

Which has better valuation and earnings, BTG or HVO?

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BTG £159.40M 1.18 N/A £6.00 19.53 hVIVO £46.77M 1.02 £17.84M -£0.87 N/A

Is BTG or HVO more profitable?

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets BTG N/A N/A N/A hVIVO -12.48% -14.65% 11.97%

Do analysts prefer ARIX or HVO?

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arix Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better earnings & valuation, ARIX or HVO?

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arix Bioscience £14.16M 0.00 £14.96M £0.11 N/A hVIVO £46.77M 1.02 £17.84M -£0.87 N/A

Is ARIX or HVO more profitable?

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets Arix Bioscience 105.64% 6.41% 2.18% hVIVO -12.48% -14.65% 11.97%

Do analysts recommend HVO or CIR?

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts plainly believe hVIVO is more favorable than Circassia Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Circassia Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend TILS or HVO?

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

hVIVO (HVO) Competitors

GBX 6.95 -0.30 (-4.14%)

As of 12:03 PM Eastern

Compare

HVO vs. SCLP, BTG, ARIX, CIR, and TILS

Should you buy hVIVO stock or one of its competitors? MarketBeat compares hVIVO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with hVIVO include Scancell (SCLP), BTG (BTG), Arix Bioscience (ARIX), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does hVIVO compare to Scancell?

hVIVO (LON:HVO) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, Scancell had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for Scancell and 0 mentions for hVIVO. hVIVO's average media sentiment score of 0.00 equaled Scancell'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Scancell	Neutral

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts plainly believe hVIVO is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A
Scancell	£4.71M	40.53	-£6.75M	-£0.55	N/A

hVIVO has a net margin of -12.48% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Scancell	-116.98%	90.29%	-45.28%

hVIVO has a beta of 1.724, indicating that its stock price is 72% more volatile than the broader market. Comparatively, Scancell has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

hVIVO beats Scancell on 10 of the 15 factors compared between the two stocks.

How does hVIVO compare to BTG?

BTG (LON:BTG) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

hVIVO has lower revenue, but higher earnings than BTG. hVIVO is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BTG	£159.40M	1.18	N/A	£6.00	19.53
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

In the previous week, BTG had 7 more articles in the media than hVIVO. MarketBeat recorded 7 mentions for BTG and 0 mentions for hVIVO. BTG's average media sentiment score of 0.04 beat hVIVO's score of 0.00 indicating that BTG is being referred to more favorably in the media.

Company	Overall Sentiment
BTG	Neutral
hVIVO	Neutral

BTG presently has a consensus target price of GBX 160, indicating a potential upside of 36.54%. hVIVO has a consensus target price of GBX 15, indicating a potential upside of 115.83%. Given hVIVO's higher possible upside, analysts clearly believe hVIVO is more favorable than BTG.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BTG	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

19.7% of BTG shares are owned by institutional investors. Comparatively, 11.8% of hVIVO shares are owned by institutional investors. 19.7% of BTG shares are owned by company insiders. Comparatively, 4.9% of hVIVO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BTG has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. BTG's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BTG	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

BTG pays an annual dividend of GBX 4.30 per share and has a dividend yield of 3.7%. hVIVO pays an annual dividend of GBX 0.20 per share and has a dividend yield of 2.9%. BTG pays out 71.7% of its earnings in the form of a dividend. hVIVO pays out -23.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

BTG beats hVIVO on 13 of the 16 factors compared between the two stocks.

How does hVIVO compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 11.8% of hVIVO shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by insiders. Comparatively, 4.9% of hVIVO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Arix Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arix Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Arix Bioscience's average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Arix Bioscience	Neutral
hVIVO	Neutral

Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market. Comparatively, hVIVO has a beta of 1.724, meaning that its stock price is 72% more volatile than the broader market.

hVIVO has higher revenue and earnings than Arix Bioscience. hVIVO is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

Arix Bioscience has a net margin of 105.64% compared to hVIVO's net margin of -12.48%. Arix Bioscience's return on equity of 6.41% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
hVIVO	-12.48%	-14.65%	11.97%

Summary

hVIVO beats Arix Bioscience on 7 of the 13 factors compared between the two stocks.

How does hVIVO compare to Circassia Group?

hVIVO (LON:HVO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Circassia Group has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Circassia Group's return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Circassia Group	N/A	N/A	N/A

11.8% of hVIVO shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts plainly believe hVIVO is more favorable than Circassia Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Circassia Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has higher revenue and earnings than Circassia Group. hVIVO is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Circassia Group	Neutral

Summary

hVIVO beats Circassia Group on 7 of the 11 factors compared between the two stocks.

How does hVIVO compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

hVIVO has higher revenue and earnings than Tiziana Life Sciences. hVIVO is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A
hVIVO	£46.77M	1.02	£17.84M	-£0.87	N/A

11.8% of hVIVO shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Tiziana Life Sciences' return on equity of 0.00% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
hVIVO	-12.48%	-14.65%	11.97%

hVIVO has a consensus target price of GBX 15, suggesting a potential upside of 115.83%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Tiziana Life Sciences had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for hVIVO. Tiziana Life Sciences' average media sentiment score of 0.00 equaled hVIVO'saverage media sentiment score.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
hVIVO	Neutral

Summary

hVIVO beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HVO vs. The Competition

Export

Metric	hVIVO	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£47.84M	£496.86M	£6.80B	£2.77B
Dividend Yield	2.68%	3.86%	2.68%	6.16%
P/E Ratio	-7.99	3.18	25.79	366.66
Price / Sales	1.02	7,182.40	550.58	85,978.63
Price / Cash	4.94	13.13	46.33	27.87
Price / Book	1.25	88.54	10.77	7.76
Net Income	£17.84M	-£96.07M	£3.57B	£5.89B
7 Day Performance	-11.60%	1.95%	3.15%	-0.71%
1 Month Performance	-14.20%	0.80%	2.34%	-1.20%
1 Year Performance	-40.34%	72.01%	33.42%	65.93%

hVIVO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HVO hVIVO	1.9103 of 5 stars	GBX 6.95 -4.1%	GBX 15 +115.8%	-39.1%	£47.84M	£46.77M	N/A	N/A	Gap Down
SCLP Scancell	N/A	GBX 19 -7.3%	N/A	+95.9%	£197.18M	£4.71M	N/A	51	News Coverage
BTG BTG	4.5563 of 5 stars	GBX 119 -0.8%	GBX 160 +34.5%	N/A	£191.72M	£159.40M	19.83	4,690
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:HVO) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

hVIVO (HVO) Competitors

HVO vs. SCLP, BTG, ARIX, CIR, and TILS

How does hVIVO compare to Scancell?

Summary

How does hVIVO compare to BTG?

Summary

How does hVIVO compare to Arix Bioscience?

Summary

How does hVIVO compare to Circassia Group?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

hVIVO (HVO) Competitors

HVO vs. SCLP, BTG, ARIX, CIR, and TILS

How does hVIVO compare to Scancell?

Does the media refer more to HVO or SCLP?

Do analysts rate HVO or SCLP?

Which has better valuation and earnings, HVO or SCLP?

Is HVO or SCLP more profitable?

Which has more volatility and risk, HVO or SCLP?

Do insiders and institutionals hold more shares of HVO or SCLP?

Summary

How does hVIVO compare to BTG?

Which has better valuation and earnings, BTG or HVO?

Does the media refer more to BTG or HVO?

Do analysts rate BTG or HVO?

Do insiders & institutionals have more ownership in BTG or HVO?

Is BTG or HVO more profitable?

Is BTG or HVO a better dividend stock?

Summary

How does hVIVO compare to Arix Bioscience?

Do institutionals and insiders hold more shares of ARIX or HVO?

Do analysts prefer ARIX or HVO?

Does the media prefer ARIX or HVO?

Which has more volatility & risk, ARIX or HVO?

Which has better earnings & valuation, ARIX or HVO?

Is ARIX or HVO more profitable?

Summary

How does hVIVO compare to Circassia Group?

Is HVO or CIR more profitable?

Do institutionals and insiders believe in HVO or CIR?

Do analysts recommend HVO or CIR?

Which has higher earnings & valuation, HVO or CIR?

Does the media prefer HVO or CIR?

Summary

How does hVIVO compare to Tiziana Life Sciences?

Which has better valuation & earnings, TILS or HVO?

Do institutionals and insiders hold more shares of TILS or HVO?

Is TILS or HVO more profitable?

Do analysts recommend TILS or HVO?

Does the media prefer TILS or HVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HVO vs. The Competition

hVIVO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools